Enerzair®
COMBINATIONS (TRIO)
INHALED CORTICOSTEROID + LONG-ACTING MUSCARINIC ANTAGONIST + LONG-ACTING BETA-2 AGONIST (ICS + LAMA + LABA)
Class
Inhaled corticosteroid (ICS)
Long-acting muscarinic antagonist (LAMA)
Long-acting beta-2 agonist (LABA)
Active ingredient
Mometasone furoate
Glycopyrronium (as bromide)
Indacaterol (as acetate)
Device
- Breezhaler®
Age
- 18 +
Typical use
Asthma
uncontrolled on high doses ICS + LABA
COPD
no common use
Marketed strength
- 160/50/150 mcg
Number of doses
- 30 capsules
Dose indicator
- Yes | Number of capsules
Usual adult dosage
High | 160/50/150 mcg – 1 inh QD
Usual pediatric dosage
-
Required inspiratory flow
> 50 L/min
Low internal resistance (R1)
Public coverage
All provinces except YT | Restricted Benefit with criteria
YT | Not a Benefit
Advantages
- Low cost
- Once daily dosing
- All the daily medication in one inhaler
- Low internal resistance (less effort required for inhalation)
- Clear capsule which ensures complete inhalation
Disadvantages
- Capsule handling required
- The capsule may get stuck while rotating during inhalation
- Capsule may be ingested
Product monograph
Download